Key Players
Competitive Landscape
Supplier competition across the coronary stents landscape spans global Tier-1 interventional cardiology multinationals, European and Japanese specialty scaffold engineers, and high-volume Asian manufacturers. US cardiovascular groups Abbott and Boston Scientific along with Medtronic anchor hospital cath-lab consignment contracts with their flagship XIENCE and Onyx Frontier platforms. Specialty innovators Terumo Corporation, Biotronik, and B. Braun compete through abluminal bioabsorbable-polymer, silicon-carbide-coated, and polymer-free stent designs. At the same time, MicroPort and Biosensors along with Meril and Lepu capture high-volume hospital tenders across Asia-Pacific and Latin America. Hospital value analysis committees qualify suppliers on five-year target-lesion failure durability and 30-day high-bleeding-risk antiplatelet labels.
Advancement of bioabsorbable-polymer and high-bleeding-risk drug-eluting stents paired with intravascular lithotripsy and AI-guided imaging consoles has become the primary strategic focus from 2025 onward. Rather than competing solely on bare stent unit price, leading device makers are bundling calcium-modification catheters, CT-guided PCI planning software, and expanded regulatory indications. In October 2026, Boston Scientific reported USD 3.406 billion in Q3 2026 Cardiovascular net sales and formed a strategic collaboration with Heartflow to integrate CT-guided PCI planning with its AVVIGO+ guidance system. Strengthening calcified-lesion preparation prior to XIENCE stenting, Abbott reported USD 803 million in Q2 2026 Vascular sales in July 2026 and positive 30-day TECTONIC coronary lithotripsy results in November 2026. Meanwhile, MicroPort surpassed 10 million cumulative stent shipments, secured CE MDR certification for Firehawk in April 2026, and entered NMPA innovative review for FireShield in September 2026.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| October 2026: Boston Scientific reported USD 3.406B in Q3 2026 Cardiovascular sales and partnered with Heartflow on CT-guided PCI planning. | Complex multivessel coronary cases require pre-procedural physiological and anatomical sizing. | Tier-1 cardiovascular leaders integrate AI CT planning with intravascular imaging consoles. | Integrated imaging and SYNERGY XD stent contracts capture hospital system tenders. |
| November 2026: Abbott Laboratories announced strong 30-day TECTONIC trial results for its SonicForce coronary intravascular lithotripsy system. | Elderly diabetic PCI patients increasingly present with severely calcified coronary plaques. | Cardiovascular leaders pair calcium-fracturing lithotripsy catheters with XIENCE stent delivery. | Bundled lesion-preparation and stent contracts lock in multi-year hospital cath-lab share. |
| April & September 2026: MicroPort received EU CE MDR certification for three core coronary products and NMPA innovative review for FireShield. | European MDR compliance and acute coronary perforation management raise regulatory bars. | Asian stent innovators expand abluminal-groove DES and covered stents into Europe. | CE MDR certified value-tier DES win cost-conscious European hospital tenders. |
| January & March 2025: Biotronik expanded Orsiro Mission indications and Terumo secured EU MDR high-bleeding-risk certification for Ultimaster Nagomi. | Large-vessel bifurcations and elderly anticoagulated patients require tailored stent specs. | Manufacturers secure dedicated regulatory labels for 5.0 mm diameters and 30-day DAPT. | Expanded on-label indications reduce off-label liability for hospital cath-lab operators. |
Source: Future Market Insights, Coronary Stents Market Report, 2026-2036.
Recent bioabsorbable-polymer clinical trials and CE MDR clearances confirm that winning hospital cath-lab tenders requires pairing 60-micron strut deliverability with verified 30-day DAPT safety. Manufacturers that bundle ultrathin stents with IVUS imaging and intravascular lithotripsy catheters are projected to capture multi-year hospital system contracts through 2036.
How are key market participants positioned in the coronary stents market?
Abbott and Boston Scientific along with Medtronic lead global full-line cath-lab contracting. Terumo and Biotronik specialize in biodegradable-polymer stents while MicroPort and Biosensors scale tender volume.
What qualification or purchasing requirements matter most to prospective buyers?
Hospital value analysis committees and cath-lab directors require five-year target-lesion failure rates below 6% and full diameter matrices from 2.0 to 5.0 millimeters. Procurement teams also mandate FDA or CE MDR approval covering abbreviated 30-day antiplatelet regimens for bleeding-prone cohorts.
Which product or application capabilities distinguish the leading companies?
Top manufacturers differentiate through 60-micron cobalt-chromium or platinum-chromium struts, abluminal groove-filled or bioabsorbable PLGA drug coatings, and integrated optical coherence tomography and lithotripsy capital equipment.
How does geographic reach differ among the key market players?
Medtronic and Abbott as well as Boston Scientific and Terumo maintain direct field teams across North America, Europe, and Japan. MicroPort and Lepu anchor Chinese hospital procurement while expanding rapidly across European and emerging-market tenders.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Abbott Laboratories | Global cardiovascular leader supplying XIENCE Skypoint, XIENCE PRO, and Ultreon OCT-guided coronary intervention. | Reported USD 803M in Q2 2026 Vascular sales in July 2026 and positive 30-day TECTONIC coronary lithotripsy trial data in November 2026. |
| Boston Scientific Corporation | Interventional cardiology leader manufacturing SYNERGY XD, SYNERGY MEGATRON, and Promus ELITE platinum-chromium stents. | Reported USD 3.406B in Q3 2026 Cardiovascular net sales and partnered with Heartflow on CT-guided PCI planning in October 2026. |
| Medtronic plc | Global medical technology leader supplying Onyx Frontier and Resolute Onyx zotarolimus-eluting coronary stents. | Published CY2026 Coronary CPT and ASC reimbursement updates and validated 4.5% 12-month TLF across RESOLUTE trials. |
| Terumo Corporation | Tokyo-based cardiovascular specialist manufacturing Ultimaster Nagomi and Ultimaster Tansei bioabsorbable-polymer sirolimus DES. | Received European MDR certification in March 2025 for Ultimaster Nagomi and Tansei in high-bleeding-risk patients. |
| Teleflex Incorporated | German vascular intervention pioneer engineering 60-micron Orsiro Mission CoCr DES and Magmaris/Freesolve magnesium scaffolds. | Introduced two expanded clinical indications for Orsiro Mission in January 2025 and demonstrated 98.49% ACS success for Magmaris in May 2026. |
| MicroPort Scientific Corporation | Shanghai-based global interventional cardiology manufacturer producing Firehawk abluminal-groove rapamycin target-eluting stents. | Surpassed 10 million global coronary stent shipments in October 2025, won CE MDR approval in April 2026, and advanced FireShield in September 2026. |
| Biosensors International Group | Singapore-headquartered developer of BioFreedom Ultra polymer-free Biolimus A9 and BioMatrix Alpha biodegradable-polymer stents. | Evaluated across NHS Supply Chain frameworks in NICE HealthTech Guidance HTG747 for high-bleeding-risk and routine PCI. |
| B. Braun SE | German healthcare manufacturer supplying Coroflex ISAR NEO polymer-free sirolimus-eluting stents and SeQuent Please Neo DCBs. | Validated across 37 Korean hospitals in the 3-year HOST-IDEA abbreviated DAPT trial and UK NICE HTG747 frameworks. |
| Meril Life Sciences Pvt. Ltd. | Indian global medtech innovator manufacturing BioMime, BioMime Branch, BioMime Morph, and EverMine 50 biodegradable-polymer DES. | Included among the 29 CE-marked NHS Supply Chain drug-eluting stents evaluated in NICE HealthTech Guidance HTG747. |
| Lepu Medical Technology Co. Ltd. | Beijing-based cardiovascular manufacturer producing GuReater, Partner, and NeoVas bioresorbable coronary stent systems. | Supplies domestic Chinese hospital VBP tenders and emerging-market catheterization laboratories. |
Research Methodology
Evaluation of the coronary stents market combined primary interviews with interventional cardiologists, hospital cath-lab materials managers, and cardiovascular device reimbursement directors with national PCI registry datasets and FDA/PMDA/CE regulatory filings. Volume-to-value modeling converts annual percutaneous coronary intervention procedures and average stents implanted per case into institutional expenditure across platforms. Final figures isolate coronary artery stents and exclude peripheral vascular and neurovascular stents.